TPTroy H. Puar

Troy H. Puar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Troy H. Puar has a total of 393 co-authors. Here are the top co-authors by number of shared publications:

  • Meifen Zhang

    Department of Endocrinology, Changi General Hospital , Singapore 529889 , Singapore

    7 shared publications
  • Joan Khoo

    Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    6 shared publications
  • Peng Chin Kek

    Department of Endocrinology, Singapore General Hospital , Singapore 169608 , Singapore

    5 shared publications
  • Adina F. Turcu

    Division of Metabolism, Endocrinology, and Diabetes, University of Michigan , Ann Arbor, MI 48109

    4 shared publications
  • Donovan Tay

    Department of Endocrinology, Sengkang General Hospital, SingHealth, Singapore

    4 shared publications
  • Lynette Lee

    Department of Endocrinology, Singapore General Hospital, SingHealth, Singapore; Department of Endocrinology, Changi General Hospital, SingHealth, Singapore

    4 shared publications

Latest Publications

  • Salt-Sensitive Hypertension Begins With Intracellular K + and Water Loss

    by Shintaro Minegishi, Norihiko Morisawa, Johannes Wild, Yam Wan Keat, Kaoru Takase-Minegishi, Adriana Marton, Tzy Tiing Lim, Manuela Peukert, Regina Lohmayer, Stephen Walsh, et al.

    BACKGROUND: Na + and water overload due to inappropriately low renal salt and water excretion is considered the root cause of salt-sensitive hypertension. However, experimental renal and psoriasis hypertension are characterized by chronic predisposition to dehydration. We tested the validity of this alternative hypertension due to loss of water theory in deoxycorticosterone acetate (DOCA) salt-sensitive hypertension. METHODS: We tested the effect of DOCA (25 mg pellet) in mice on a low Na + diet (0.02%–0.03%) with tap water, or with Na + in their drinking water (1% NaCl or 1.44% NaHCO 3 ), on body Na + , K + , and water content 2, 6, and 12 days after treatment initiation. We monitored blood pressure with radio-telemetry, food and water intake, and renal electrolyte and water excretion. RESULTS: At day 2, DOCA NaCl-treated mice elevated blood pressure during a state of isolated body K + and water loss, indicating substantial intracellular dehydration. Although increasing their fluid intake and urine output, the mice reduced the excretion of free water, indicating renal water conservation. At days 6 and 12, secondary Na + retention occurred, which replaced the amount of K + lost and corrected the dehydration, albeit at the expense of an intracellular Na + /K + redistribution disorder. DOCA NaHCO 3 -treated mice with Na + -resistant blood pressure showed a comparable Na + /K + redistribution disorder, but without accompanying early dehydration due to earlier replacement of lost K + by Na + . CONCLUSIONS: Experimental DOCA salt-sensitive hypertension initiates with a systemic water conservation response in the face of K + -driven intracellular water loss. Both dehydration and blood pressure increase could be causally treated by oral K + supplementation.

  • Aldosterone-Producing Lesions Harboring ATP1A1 and ATP2B3 Mutations: An International Multicenter Study

    by Peeradon Vibhatavata, Yueting Liu, Madson Q. Almeida, Laurence Amar, Irina Bancos, Stephanie Baron, Frederike Butz, Debbie L. Cohen, Silas A. Culver, Fabio Luiz Fernandes-Rosa, et al.

    BACKGROUND: Somatic aldosterone-driver mutations are identified in >90% of patients with primary aldosteronism undergoing adrenalectomy, and they display distinct demographic clustering. ATP1A1 and ATP2B3 mutations, encoding the Na + /K + ATPase α1 subunit and the Ca 2+ ATPase 3, respectively, are relatively rare and are often grouped as ATPase mutations. Differences in their clinical and biochemical phenotypes remain understudied. METHODS: This international collaboration of 16 centers included patients with primary aldosteronism harboring pathogenic variants in ATP1A1 and ATP2B3 . Clinical data were collected from medical records. Where available, we compared histopathologic features and steroid profiles (from peripheral and adrenal vein samples) by liquid chromatography-tandem mass spectrometry. RESULTS: We included 300 patients (mean age, 57±11 years; 85% men) with aldosterone-producing lesions harboring ATP1A1 (204) and ATP2B3 (96) mutations. Age and sex distributions were similar. ATP2B3 mutations were associated with lower serum potassium, higher lateralization indices, and stronger contralateral suppression. Postoperative biochemical cure was achieved in 96% of patients with ATP2B3 mutations versus 83% of those with ATP1A1 mutations ( P =0.02). Multiple CYP11B2-positive lesions were observed in 47% of ATP1A1 versus 27% of ATP2B3 cases ( P =0.03). Baseline peripheral steroid profiling was available in 126 patients (84 with ATP1A1 and 42 with ATP2B3 ) and showed higher aldosterone concentrations in the ATP2B3 group (median [interquartile range], 31 ng/dL [20–43] versus 23 ng/dL [11–38]; P =0.03). CONCLUSIONS: ATP ase mutations are most common in middle-aged men with lateralized primary aldosteronism. Compared with ATP1A1 , ATP2B3 mutations are associated with a more severe primary aldosteronism phenotype, stronger lateralization, and higher rates of single aldosterone-producing lesions and postoperative biochemical cure.

  • Oral KCl Supplementation Safely Reduces Body Na + Surplus and Blood Pressure

    by Adriana Marton, Hieu T.N. Tran, Norihiko Morisawa, Ismail Osman, Seyed Ehsan Saffari, Tzy Tiing Lim, Wan Keat Yam, Matthew B. Chuah, Wei Lin Tay, Wai Lun Moy, et al.

    BACKGROUND: Potassium-enriched table salt lowers blood pressure (BP) and reduces cardiovascular mortality. Whether these beneficial effects stem from reduced Na + intake, increased K + intake, or both is unknown. We tested the hypothesis that oral potassium chloride (KCl) supplementation lowers body Na + content and BP in patients with essential hypertension (EH) or hyperaldosteronism, independent of salt intake. METHODS: Between February 2024 and February 2025, we conducted a single-arm, prospective, longitudinal study with nonrandomized oral KCl intervention in 40 participants with hypertension. All received personalized (blood K + -adjusted) KCl supplementation (SPAN-K tablets, potassium chloride 600 mg; Aspen Pharmacare Australia Pty, Ltd) for 6 to 9 weeks. After the intervention, participants completed a routine diagnostic workup and were classified with EH or hyperaldosteronism. Primary end point: baseline muscle Na + surplus in hyperaldosteronism. Secondary end point: interventional muscle Na + mobilization and BP reduction. RESULTS: Seventeen participants were diagnosed with EH, and 23 with hyperaldosteronism. At baseline, patients with hyperaldosteronism showed higher muscle Na + content (24.67±2.93 versus 22.48±3.37 mmol/L tissue volume, P =0.023; primary end point). Oral KCl increased 24-hour urine K + excretion without altering 24-hour urine Na + . KCl supplementation successfully eliminated the muscle Na + surplus in the hyperaldosteronism group (−1.90 mmol/L tissue volume [95% CI, −3.20 to −0.60]; P =0.005; secondary end point), lowered blood Na + /K + ratios in both groups (EH, −5.34 [95% CI, −7.69 to −2.99]; P =4.6×10 -5 ; hyperaldosteronism, −7.02 [95% CI, −9.04 to −5.01]; P =2.1×10 -8 ), and reduced systolic BP (EH, −8.33 mm Hg [95% CI, −14.55 to −2.12]; P =0.010; hyperaldosteronism, −7.35 mm Hg [95% CI, −12.69 to −2.01]; P =0.008). To account for early study termination, a conservative significance threshold of α=0.025 was implemented, which all end points crossed. CONCLUSIONS: Oral KCl supplementation mobilizes intracellular Na + stores, corrects pathological Na + /K + distribution, and lowers BP across hypertension phenotypes. This safe, targeted approach warrants consideration as a scalable public health strategy for cardiovascular disease prevention. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06569589.


  • Primary Aldosteronism Medical Treatment Outcomes (PAMO) Beyond 12 Months

    by Jun Yang, Jessica Goi, Jacopo Burrello, Martin Reincke, Christian Adolf, Denise Brüdgam, Qifu Li, Ying Song, Jinbo Hu, Shumin Yang, et al.

    BACKGROUND: Primary aldosteronism (PA) is a common and treatable cause of hypertension, yet data on the durability of medical treatment response beyond the first year are limited. Using the PA medical treatment outcomes framework, we evaluated long-term biochemical and clinical outcomes and factors associated with treatment response. METHODS: We conducted an international, multicenter, observational cohort study across 27 centers on 4 continents. Adults with PA treated with mineralocorticoid receptor antagonists and/or epithelial sodium channel blockers between 2016 and 2021 were included if follow-up data were available at ≥12 months. Biochemical and clinical responses were classified as complete, partial, or absent using PA medical treatment outcomes criteria. Ordinal logistic regression identified determinants of a favorable treatment response. RESULTS: The cohort included 1292 patients (47.5% women, mean age 52 years) with a median follow-up of 34 months (interquartile range, 21–51). At ≥12 months, 58.3% achieved a complete biochemical response, and 20.8% achieved a complete clinical response, with only 5% showing no response. Determinants of a favorable biochemical response included lower aldosterone and lateralization index, and higher renin and potassium levels at baseline. In those taking spironolactone, a higher daily dose was also associated with a favorable biochemical response. Determinants of a favorable clinical response included female sex, lower body mass index, shorter duration of hypertension, and absence of hypertension-mediated organ damage. CONCLUSIONS: Targeted medical therapy for PA can deliver sustained biochemical and clinical benefits. Early disease detection and adequate dose titration are highly actionable determinants of long-term treatment success.


  • Cardiometabolic Burden in Bilateral Macronodular Adrenal Disease With Primary Aldosteronism

    by Annalisa Panarelli, Marta Araujo-Castro, Livia M. Mermejo, Adina F. Turcu, Jung Hee Kim, Seung Shin Park, Fabio Bioletto, Mirko Parasiliti-Caprino, Masakatsu Sone, Athina Markou, et al.

    BACKGROUND: Bilateral macronodular adrenocortical disease is often linked to autonomous cortisol secretion, but may also present with primary aldosteronism (PA). METHODS: This international (Europe, United States, Asia) retrospective cohort study included adults with radiological evidence of bilateral macronodular adrenocortical disease and biochemically confirmed PA. The primary endpoints was major adverse cardiovascular events (MACE); secondary end points included cardiometabolic comorbidities and surgical outcomes per PA surgical outcome criteria. RESULTS: Two hundred forty-nine patients from 41 centers in 12 countries were included (median age, 55 years; 62% male). Median hypertension duration at PA diagnosis was 9.9 years. Among 178 tested, 52% had cortisol cosecretion and 47% isolated PA. At baseline, 56% had metabolic comorbidities, and 16% had ≥1 MACE. Patients with MACE were older, more often male, had longer hypertension duration, and higher diabetes rates. Eighty-nine patients underwent adrenalectomy: 50 without MRA (mineralocorticoid receptor antagonists), 38 with MRA, and 1 with steroidogenesis inhibitors. One hundred twenty-four patients received continued MRA without adrenalectomy or steroidogenesis inhibitors. Adrenal venous sampling showed lateralized PA in 89% of surgical versus 19% of MRA-treated patients ( P P =0.2), MACE occurred in 8% and 6%, respectively ( P =1.0). Blood pressure and organ damage were similar, but more MRA-treated patients needed ≥3 antihypertensives (MRA: 48% versus adrenalectomy: 14%; P <0.001). Among operated patients, complete clinical and biochemical success was 26% and 71%, respectively. CONCLUSIONS: Bilateral macronodular adrenocortical disease with PA carries a high cardiometabolic burden. Early detection and precise subtyping are key to optimizing management and preventing target organ damage.

  • Open Access

    Approach to the Patient With Primary Aldosteronism: Role of Molecular Imaging

    by Ada E D Teo, Hieu T N Tran, Chin Meng Khoo, Ismail Osman, Aaron Kian-Ti Tong, Roger S Y Foo, Troy H Puar

    A common yet underdiagnosed cause of secondary hypertension, primary aldosteronism (PA) is characterized by excess aldosterone production, causing hypertension with increased risk of cardio-renal-metabolic complications. Accurate and timely localization of the source of aldosterone excess is crucial for management, in the form of curative adrenalectomy for unilateral aldosterone-producing adenoma or medical management for bilateral adrenal hyperplasia. The current diagnostic algorithm involves adrenal vein sampling (AVS) as the current “gold standard” in determining lateralization of aldosterone secretion, but its technical challenges present significant barriers to timely diagnosis and treatment. Recent technological advancements have contributed to the evolution of molecular imaging modalities such as 11C-metomidate positron emission tomography-computed tomography (11C-MTO PET-CT). Improved molecular imaging modalities hold significant potential to complement existing diagnostic pathways and refine treatment strategies for PA. This review evaluates different case scenarios comparing the utility of AVS with 11C-MTO PET-CT, suggesting a practical approach for its interpretation and highlighting the clinical decision-making process.


  • Open Access

    A global real-world study assessing total time to adrenalectomy in primary aldosteronism

    by Charmaine Ter, Xuan Han Koh, Hieu Tran, Irina Bancos, Mohamed Bassiony, Marta Araujo-Castro, Miguel Paja, Marga González Boillos, Eleftheria Gkaniatsa, Martin Reincke, et al.

    Background: Primary aldosteronism (PA) is a common treatable cause of hypertension. When caused by unilateral adrenal disease, it is potentially curable by adrenalectomy. However, specialized tests and other factors may delay definitive treatment. We assessed the time to adrenalectomy (TTA) for patients worldwide. Methods: We conducted an international, multicentre retrospective study involving 39 centres from 15 countries to determine the total time taken from the first presentation to adrenalectomy and the intervals between each stage (screening, confirmatory, subtyping, and adrenalectomy). We included patients with PA who underwent adrenalectomy from January 1, 2018, to October 30, 2022. Post-adrenalectomy outcomes were evaluated using the Primary Aldosteronism Surgery Outcome criteria. We performed multivariable quantile and linear regression to identify characteristics associated with longer TTA. Results: We included 861 patients, mean age 49.3 ± 11.1 years, and 44.5% were women. Overall median TTA was 13.5 months, IQR: 6.6-24.5. Median intervals were 0.1 months (screening), 1.0 months (confirmatory), 4.1 months (subtyping), and 4.3 months (adrenalectomy). On multivariable analysis, median TTA was increased by 5.4 months for each additional adrenal vein sampling (AVS) procedure. Other factors associated with longer TTA included adrenalectomy post-COVID-19, younger age, and additional screening tests. Compared with countries with routine AVS, those without AVS had a shorter TTA (6.1 vs 15.1 months, P < .001), but greater likelihood of absent/partial biochemical success post-adrenalectomy (27.4% vs 12.4%, P < .001). Conclusion: Primary aldosteronism management is time-consuming worldwide, especially for subtyping tests and adrenalectomy. While omitting AVS reduces overall time, patients are less likely to achieve biochemical cure post-adrenalectomy.


  • Expert Consensus on the Primary Aldosteronism Severity Classification and its strategic application in indicating adrenal venous sampling

    by Masanori Murakami, Mitsuhide Naruse, Hiroki Kobayashi, Mirko Parasiliti-Caprino, Fabio Bioletto, Denise Brüdgam, Isabel Stüfchen, Martin Reincke, Matthieu St-Jean, Ivana Kraljevic, et al.

    Objective: Severity classifications are essential for many diseases to prioritize patient management tasks such as diagnosis, treatment, and follow-up. Primary aldosteronism (PA), a common cause of secondary hypertension, lacks a standardized severity scale despite generally requiring invasive diagnostics like adrenal venous sampling (AVS). This study aimed to develop a global expert consensus-based classification for PA severity to improve clinical decision-making. Methods: A panel of 45 international experts from 40 centers across four continents used the Delphi method to create a consensus severity classification for PA. This classification was then applied retrospectively to 2593 PA patients from 26 centers to assess its association with the disease subtype. Results: After four rounds, the Primary Aldosteronism Severity Classification (PASC), which integrates biochemical and clinical parameters including serum potassium, blood pressure, and basal plasma aldosterone concentration, was established. Primary Aldosteronism Severity Classification classifies PA into mild (3 and 4 points), moderate (5-7 points), and severe (8 and 9 points). Among the cohort from 26 centers, 13.9%, 63.0%, and 23.1% were classified as mild, moderate, and severe, respectively, aligning with lateralized subtype prevalence rates of 14.7%, 44.6%, and 72.6%. Conclusion: Primary Aldosteronism Severity Classification is a newly developed simplified, semi-quantitative classification of PA severity. The correlation between PASC and lateralized PA subtype supports its potential to provide graded recommendations of AVS prior to surgical indication in each patient.


  • Open Access

    Health Care Challenges in the Management of Primary Aldosteronism in Southeast Asia

    by Norlela Sukor, Sarat Sunthornyothin, Thang V Tran, Tri Juli Tarigan, Leilani B Mercado-Asis, Satha Sum, Moe Wint Aung, Alice M L Yong, Tania Tedjo, Michael Villa, et al.

    Context: While guidelines have been formulated for the management of primary aldosteronism (PA), following these recommendations may be challenging in developing countries with limited health care access. Objective: We aimed to assess the availability and affordability of health care resources for managing PA in the Association of Southeast Asian Nations (ASEAN) region, which includes low-middle-income countries. Methods: We instituted a questionnaire-based survey to specialists managing PA, assessing the availability and affordability of investigations and treatment. Population and income status data were taken from the national census and registries. Results: Nine ASEAN country members (48 respondents) participated. While screening with aldosterone-renin ratio is performed in all countries, confirmatory testing is routinely performed in only 6 countries due to lack of facilities and local assays, and cost constraint. Assays are locally available in only 4 countries, and some centers have a test turnaround time exceeding 3 weeks. In 7 countries (combined population of 442 million), adrenal vein sampling (AVS) is not routinely performed due to insufficient radiological facilities or trained personnel, and cost constraint. Most patients have access to adrenalectomy and medications. In 6 countries, the cost of AVS and adrenalectomy combined is more than 30% of its annual gross domestic product per capita. While most patients had access to spironolactone, it was not universally affordable. Conclusion: Large populations currently do not have access to the health care resources required for the optimal management of PA. Greater efforts are required to improve health care access and affordability. Future guideline revisions for PA may need to consider these limitations.


  • Prolonged Hypokalemia and Delayed Diagnosis of Primary Aldosteronism: Clinical Course and Risk Factors

    by Gaytri Gupta, Ada E D Teo, Du Soon Swee, Lih Ming Loh, Matthew Chuah, Wann Jia Loh, Seyed Ehsan Saffari, Xuan Han Koh, Peng Chin Kek, Troy H Puar

    Introduction Primary Aldosteronism (PA) is a common cause of hypertension. However, diagnosis is often delayed, leading to poorer clinical outcomes. Hypokalemia with hypertension is characteristic of PA, and is an indication for screening. We evaluated if patients with PA had prolonged hypokalemia before diagnosis, the subsequent biochemical/clinical control, and factors associated with delayed diagnosis. Methods Our study included all PA patients with hypokalemia diagnosed between 2001 to 2022. Delayed diagnosis was defined as duration of hypokalemia of >1 year from first occurrence, to first evaluation by a PA specialist. Patients were reassessed post–adrenalectomy using the Primary Aldosteronism Surgery Outcomes criteria. We performed multivariable analysis to assess for factors associated with delayed diagnosis. Results Among 240 patients with PA who presented with hypokalemia, 122 (51%) patients had delayed diagnosis, with prolonged hypokalemia of median duration 4.5 (2.4–7.5) years. Patients with delayed diagnosis were older, had longer duration of hypertension, higher pill burden, lower renal function and more prevalent cardiovascular disease. Factors associated with delayed diagnosis included older age, presence of hyperlipidaemia, and less severe hypokalemia (serum potassium >3.0mmol/L). Compared to patients with early diagnosis, a lower proportion of those with delayed diagnosis underwent adrenal vein sampling (73% vs 58%), P<0.05. Sixty of 118 (50.8%) non-delayed, and 39 of 122 (32.0%) patients with delayed diagnosis underwent surgery. Conclusion Despite manifestation of hypokalemia, many patients with PA fail to be promptly screened. Greater emphasis in hypertension guidelines, and efforts to improve awareness of PA amongst primary care physicians are urgently needed.